sotrovimab + sotrovimab + sotrovimab + sotrovimab + Sotrovimab + Sotrovimab + Sotrovimab
Phase 3Terminated 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19
Trial Timeline
Jun 10, 2021 โ Mar 24, 2023
NCT ID
NCT04913675About sotrovimab + sotrovimab + sotrovimab + sotrovimab + Sotrovimab + Sotrovimab + Sotrovimab
sotrovimab + sotrovimab + sotrovimab + sotrovimab + Sotrovimab + Sotrovimab + Sotrovimab is a phase 3 stage product being developed by Vir Biotechnology for Covid19. The current trial status is terminated. This product is registered under clinical trial identifier NCT04913675. Target conditions include Covid19.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05280717 | Phase 1 | Terminated |
| NCT04913675 | Phase 3 | Terminated |
Competing Products
20 competing products in Covid19